Planning for tuberculosis (TB) control requires an assessment of the number and distribution of drug-resistant cases. This study used results of resistance surveys from 64 countries, together with data predictive of resistance rates from 72 others, to estimate the number of new multidrugresistant (MDR) TB cases that occurred in 2000. By these methods, an estimated 273,000 (95% confidence limits, 185,000 and 414,000) new cases of MDR TB occurred worldwide in 2000, 3.2% of all new TB cases. The analysis provides the first comprehensive set of estimates of the MDR TB burden by country and globally.
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The most important measure of tuberculosis (TB) drug resistance is the number of new cases that are resistant to at least isoniazid and rifampicin. The treatment of such multidrug-resistant (MDR) TB cases requires a departure from standard short-course regimens. Moreover, multiple resistance among new cases means not simply that resistance has been acquired through treatment failure but also that the resistant strains have generated new cases following transmission.
In surveys of sputum smear-positive TB patients in 64 countries [1, 2] , an average of 3.4% (weighted by incidence in each country [3] ) of new cases had MDR TB (table 1) . New cases were patients who, in response to direct questioning, denied prior treatment or treatment for >1 month and who had no documented history of treatment [2] . The highest rates were in Estonia (14%), Henan Province, China (11%), Latvia (9%), and Ivanovo (9%) and Tomsk (7%) oblasts, Russia. The countries taking part in these surveys were not selected so as to represent the worldwide distribution of drug resistance, so we cannot assume that the 3.4% average applies globally. To obtain a better estimate, we used the survey data and multiple logistic regression analysis to identify a set of variables that can predict the number of MDR TB cases in countries where no resistance surveys have yet been carried out.
Methods
Our general approach was to identify a set of independent widely measurable variables predictive of MDR TB rates by use of data collected from the 64 surveyed countries. We used the resulting regression equation, together with measures of the independent variables, to estimate MDR TB rates in 72 more countries. These 136 countries have 97% of the world's population.
For both surveyed and nonsurveyed countries, we had measures of 7 independent variables that a priori are likely to be associated with resistance: number of years of rifampicin use [1, 2] ; whether drugs were administered in fixed-dose combinations [1, 2] ; estimated TB incidence rate (as ln incidence/person/year) [3, 4] ; percent of patients receiving short-course chemotherapy [1, 2] ; percent successfully treated [1, 2] ; percent previously treated [1, 2] ; and percent coinfected with human immunodeficiency virus [1, 2] . We also included 2 indicators that might be linked indirectly to the distribution of resistance: gross national product (expressed as ln GNP) [5] and region of the world (8 areas) [3] . From this list we selected the variables with significant predictive power by using x 2 as a criterion for backward elimination in multiple logistic regression [6] .
One strength of this approach is that it allows explicit calculation of the SEs on estimates of MDR TB incidence. The errors come from 3 sources. For countries that have surveyed the proportions of TB cases carrying MDR TB, there are errors due to the finite sample sizes of the surveys (binomial errors on proportions) and to uncertainties surrounding estimates of the number of TB cases [4] . If n i is the total number of tuberculosis cases in country i and p i is the proportion that are MDR, then the total number of MDR TB cases is m i ¼ n i p i , and the variance is
The total for the surveyed countries is obtained by summing the 64 country estimates, and the variance of this total is the sum of the countryspecific variances.
The regression analysis introduces a third source of error that applies to the estimates for nonsurveyed countries. This error can be evaluated as follows. Let the proportion of drug-resistant cases measured for a particular country bepðxÞ with x ¼ ðA; B; C; ...Þ. Because the regression is done on logistically transformed data, the observed y values areŷ ¼ ln½p=ð1 2pÞ. The coefficients of ðA; B; C; . . .Þ are the elements of a vector a, the covariance matrix of the coefficients is C(a), and the covariance matrix of the estimates of the fitted points y is CðyÞ ¼ x t CðaÞx, where t indicates the transpose of the matrix. To get the covariance matrix of the fitted proportions, p(x), we use the linear term in a Taylor expansion to obtain CðpÞ ¼ F t CðyÞF, where
Then this third source of variation in the estimated number of MDR cases (E) arising from the regression is
and is computed with data from all pairs of countries i, j. To calculate the total error on estimates for 72 nonsurveyed countries, V(E ) must be added to the average variance of the point estimates for the surveyed countries and, as above, the variance associated with estimates of the numbers of TB cases.
Results

Logistic regression analysis of data from the 64 surveyed countries yielded 3 variables (treatment success [T], ln GNP [G]
, and geographic region) that together explained 44% of the variation in the MDR TB proportion p (figure 1). By grouping regions of the world that had similar MDR TB proportions, we were able to collapse the initial 8 regions to 3 that were significantly different from each other (x 2 test). Group 1 included established market economies and Latin America. Group 2 comprised eastern Europe and the eastern Mediterranean and western Pacific regions. Other African and Southeast Asian countries were in group 3. The regression equation therefore was ln½ p=ð1 2 pÞ ¼ a 1;2;3 þ bG þ cT, where the intercepts a 1,2,3 for regional groups 1-3 were 1.373 (SE, 0.390), 2.095 (SE, 0.377), and 0.425 (SE, 0.309), respectively, and the regression coefficients were b ¼ 20:312 (SE, 0.029) and c ¼ 20:037 (SE, 0.004).
We calculated the total MDR TB cases as the product of p and the estimated TB incidence for each country [1, 4] Established market economies in western Europe, North America, and Asia had ,1000 MDR TB cases in total, whereas Southeast Asia and the western Pacific regions each had . 75,000 (table 1) . Few data are available from some large countries so estimates are subject to large random errors and probably systematic errors too. We calculated that India had 63,100 new MDR TB cases in 2000, 3.4% of all new cases. But the range is wide (25,900-108,300 cases) because this result is derived from a single survey of 384 patients in Tamil Nadu. The uncertainty may be greater if resistance rates are systematically higher or lower elsewhere in the country. For China, examination of 2918 patients in 4 provinces gave a nationwide estimate of 68,400 MDR TB cases (range, 45,800-104,200). The estimate for Russia, based on examinations of all patients (including prisoners) in 3 oblasts, was 5900 (range, 3800-9000) new MDR TB cases. Table 2 lists estimates for all 136 countries. Table 3 shows the distribution of surveyed and nonsurveyed countries among the 3 geographical groups and gives the regression statistics.
For countries where resistance surveys have not yet been done, the errors may be still larger. The most significant example is Pakistan (eastern Mediterranean region), for which the best estimate is 26,200 MDR TB cases but the upper 95% CL is 62,200. These uncertainties are also reflected in our estimates of MDR TB proportions. The highest were in the eastern Europe (5.5%) and eastern Mediterranean (7.9%) regions. The range for the latter is especially large (1.7%-14.1%) because there have been no surveys in the region's most populous countries, Afghanistan, Pakistan, and Sudan.
Discussion
A drug regimen to treat TB cases resistant to isoniazid and rifampicin, negotiated through the World Health Organization's Green Light Committee, is currently 50 times more costly than the cheapest short-course regimen for drug-susceptible cases [7] . Even at this relatively favorable price, it could cost more to treat the 3.2% of new TB cases that are MDR than all other new TB cases together. Adding in the cost of managing MDR TB cases that have previously failed treatment would present a bill for drugs that is substantially greater. Because the proper management of drug-resistant patients demands in many countries a significant fraction of the overall budget for TB control, we need precise estimates of the number and distribution of resistant cases.
Our analysis provides the first comprehensive set of estimates of MDR TB burden for the 136 countries that make up 97% of the world's population. The calculations are approximatelower and upper bounds differ by a factor of about 2. However, both the size of the estimates and the uncertainty surrounding them point to the areas where resistance surveys are urgently needed. Countries that probably had .5000 new cases of MDR TB in 2000 and for which surveys are planned or are in progress include Ethiopia, Indonesia, Nigeria, the Philippines, and Sudan. Cambodia and Zambia have recently completed national surveys. Surveys are also planned or are underway in Bangladesh, China, Democratic Republic of Congo, Egypt, India, Mexico, Russia, South Africa, and Ukraine. These surveys will provide the data needed to narrow the bounds on the global estimate of MDR TB burden and, more importantly, to facilitate the effective planning of TB control within each of these countries.
